VERAXA Biotech reports in vitro data for its BiTAC-ADC platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
June 18, 2026 7:00 AM EDTBiTAC-ADC in vitro data, along with initial data from the most advanced BiTAC-TCE program recently presented at the American Association for Cancer Research (AACR) Annual Meeting, underpin the Companys two viable and clearly differentiated product platform technologies
ZURICH, SWITZERLAND June 18, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; VERAXA), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform and its potential to enable more precise and targeted cancer therapies. VERAXA will attend the BIO International Convention in San Diego,... More
